Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants

Bibliography

• National Cancer Institute. Surveillance Epidemiology and End Results. Available from: http://seer.cancer.gov [Accessed 12 November 2011]
   Google Scholar
• Moore SW, Satge D, Sasco AJ, The epidemiology of neonatal tumours: report of an international working group. Pediatr Surg Int 2003;19:509-19
   PubMedGoogle Scholar
• Gurney JG, Smith MA, Ross JA. Cancer among infants. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR, editors. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975 – 1995_(12). National Cancer Institute, SEER Program; NIH Pub. No. 99-4649 1999. p. 149-56
   Google Scholar
• Isaacs HJ. Perinatal (congenital and neonatal) neoplasms: a report of 110 cases. Pediatr Pathol 1985;3:165-216
   PubMedGoogle Scholar
• Parkes SE, Muir KR, Southern L, Neonatal tumours: a thirty-year population-based study. Med Pediatr Oncol 1994;22:309-17
   PubMedGoogle Scholar
• Beckwith JB, Perrin EV. In situ neuroblastomas: a contribution to the natural history of neural crest tumors. Am J Pathol 1963;43:1089-104
   PubMed Web of Science ®Google Scholar
• Moore SW, Kaschula ROC, Albertyn R, The outcome of solid tumors occurring in the neonatal period. Pediatr Surg Int 1995;10:366-70
   Google Scholar
• Batcup G. Cancer in the very young child - pitfalls and problems for the pathologist. Br J Cancer 1992;18:S5-7
   Google Scholar
• Look AT, Hayes FA, Shuster JJ, Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a pediatric oncology group study. J Clin Oncol 1991;9:581-91
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Nakagawara A. Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol Oncol 1992;14:111-16
   PubMedGoogle Scholar
• Biondi A, Rossi V, Di Celle PF, Unique genotypic features of infant acute lymphoblastic leukaemia at presentation and at relapse. Br J Haematol 1992;80:472-9
   PubMed Web of Science ®Google Scholar
• Ross JA, Davies SM, Potter JD, Robison LL. Epidemiology of childhood leukemia, with a focus on infants. Epidemiol Rev 1994;16:243-72
   PubMed Web of Science ®Google Scholar
• Geenen MM, Cardous-Ubbink MC, Kremer LC, Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 2007;297:2705-15
   PubMed Web of Science ®Google Scholar
• McLeod HL, Relling MV, Crom WR, Disposition of antineoplastic agents in the very young child. Br J Cancer Suppl 1992;18:S23-9
   Google Scholar
• Siegel SE, Moran RG. Problems in the chemotherapy of cancer in the neonate. Am J Pediatr Hematol Oncol 1981;3:287-96
   PubMedGoogle Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, Developmental pharmacology - Drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-67
   PubMed Web of Science ®Google Scholar
• van den Anker JN, Schwab M, Kearns GL. Developmental pharmacokinetics. Handb Exp Pharmacol 2011;205:51-75
   PubMedGoogle Scholar
• Tetelbaum M, Finkelstein Y, Nava-Ocampo AA, Koren G. Back to basics: understanding drugs in children: pharmacokinetic maturation. Pediatr Rev 2005;26:321-8
   PubMed Web of Science ®Google Scholar
• Johnson TN. The problems in scaling adult drug doses to children. Arch Dis Child 2008;93:207-11
   PubMed Web of Science ®Google Scholar
• Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther Drug Monit 2007;29:271-8
   PubMed Web of Science ®Google Scholar
• Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006;45:1077-97
   PubMed Web of Science ®Google Scholar
• Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996;30:329-32
   PubMed Web of Science ®Google Scholar
• Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008;48:303-32
   PubMed Web of Science ®Google Scholar
• Knibbe CA, Krekels EH, Danhof M. Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol 2011;7:1-8
   PubMed Web of Science ®Google Scholar
• Knibbe CA, Danhof M. Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Int J Pharm 2011;415:9-14
   PubMed Web of Science ®Google Scholar
• Booth BP, Rahman A, Dagher R, Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol 2007;47:101-11
   PubMed Web of Science ®Google Scholar
• Trame MN, Bergstrand M, Karlsson MO, Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin Cancer Res 2011;17:6867-77
   PubMed Web of Science ®Google Scholar
• Aumente D, Buelga DS, Lukas JC, Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet 2006;45:1227-38
   PubMed Web of Science ®Google Scholar
• Knibbe CA, Krekels EH, van den Anker JN, Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 2009;48:371-85
   PubMed Web of Science ®Google Scholar
• Krekels EH, DeJongh J, van Lingen RA, Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children. Clin Pharmacokinet 2011;50:51-63
   PubMed Web of Science ®Google Scholar
• Mahmood I. Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model? Br J Clin Pharmacol 2011;71:88-94
   PubMed Web of Science ®Google Scholar
• Ginsberg G, Hattis D, Sonawane B, Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 2002;66:185-200
   PubMed Web of Science ®Google Scholar
• Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005;78:260-77
   PubMed Web of Science ®Google Scholar
• Fakhoury M, Litalien C, Medard Y, Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 2005;33:1603-7
   PubMed Web of Science ®Google Scholar
• Konieczna A, Erdosova B, Lichnovska R, Differential expression of ABC transporters (MDR1, MRP1, BCRP) in developing human embryos. J Mol Histol 2011;42:567-74
   PubMed Web of Science ®Google Scholar
• Halperin EC. Neonatal neoplasms. Int J Radiat Oncol Biol Phys 2000;47:171-8
   PubMedGoogle Scholar
• Pieters R, Schrappe M, De Lorenzo P, A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007;370:240-50
   PubMed Web of Science ®Google Scholar
• Besunder JB, Reed MD, Blumer JL. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I). Clin Pharmacokinet 1988;14:189-216
   PubMed Web of Science ®Google Scholar
• Morselli PL. Clinical pharmacology of the perinatal period and early infancy. Clin Pharmacokinet 1989;17:13-28
   PubMed Web of Science ®Google Scholar
• Zemlickis D, Klein J, Moselhy G, Koren G. Cisplatin protein binding in pregnancy and the neonatal period. Med Pediatr Oncol 1994;23:476-9
   PubMedGoogle Scholar
• Urquhart BL, Kim RB. Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 2009;65:1063-70
   PubMed Web of Science ®Google Scholar
• Stam RW, den Boer ML, Meijerink JP, Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003;101:1270-6
   PubMed Web of Science ®Google Scholar
• Lacroix D, Sonnier M, Moncion A, Expression of CYP3A in the human liver–evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997;247:625-34
   PubMedGoogle Scholar
• Stevens JC, Hines RN, Gu C, Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003;307:573-82
   PubMed Web of Science ®Google Scholar
• de Wildt SN, Kearns GL, Hop WC, Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Clin Pharmacol Ther 2001;70:525-31
   PubMed Web of Science ®Google Scholar
• De Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 2005;44:1135-64
   PubMed Web of Science ®Google Scholar
• Yule SM, Boddy AV, Cole M, Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 1996;41:13-19
   PubMed Web of Science ®Google Scholar
• Krischer JP, Epstein S, Cuthbertson DD, Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997;15:1544-52
   PubMed Web of Science ®Google Scholar
• Bleyer WA. Cancer chemotherapy in infants and children. Pediatr Clin North Am 1985;32:557-74
   PubMedGoogle Scholar
• Green DM, Norkool P, Breslow NE, Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: a report from the National Wilms' Tumor Study. J Clin Oncol 1990;8:1525-30
   PubMed Web of Science ®Google Scholar
• Periclou AP, Avramis VI. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. Cancer Chemother Pharmacol 1996;39:42-50
   PubMed Web of Science ®Google Scholar
• Relling MV, Nemec J, Schuetz EG, O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994;45:352-8
   PubMed Web of Science ®Google Scholar
• Bueva A, Guignard JP. Renal function in preterm neonates. Pediatr Res 1994;36:572-7
   PubMed Web of Science ®Google Scholar
• van den Anker JN, Hop WC, de Groot R, Effects of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant. Pediatr Res 1994;36:578-81
   PubMedGoogle Scholar
• Rhodin MM, Anderson BJ, Peters AM, Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009;24:67-76
   PubMed Web of Science ®Google Scholar
• van den Anker JN. Pharmacokinetics and renal function in preterm infants. Acta Paediatr 1996;85:1393-9
   PubMed Web of Science ®Google Scholar
• Drukker A, Guignard JP. Renal aspects of the term and preterm infant: a selective update. Curr Opin Pediatr 2002;14:175-82
   PubMed Web of Science ®Google Scholar
• Aperia A, Broberger O, Elinder G, Postnatal development of renal function in pre-term and full-term infants. Acta Paediatr Scand 1981;70:183-7
   PubMed Web of Science ®Google Scholar
• van den Anker JN, van der Heijden BJ, Hop WC, The effect of asphyxia on the pharmacokinetics of ceftazidime in the term newborn. Pediatr Res 1995;38:808-11
   PubMed Web of Science ®Google Scholar
• van den Anker JN, Schoemaker RC, Hop WC, Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. Clin Pharmacol Ther 1995;58:650-9
   PubMed Web of Science ®Google Scholar
• van Overmeire B, Touw D, Schepens PJ, Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther 2001;70:336-43
   PubMed Web of Science ®Google Scholar
• Allegaert K, van den anker JN, Naulaers G, de Hoon J. Determinants of drug metabolism in early neonatal life. Curr Clin Pharmacol 2007;2:23-9
   PubMedGoogle Scholar
• Weitzman S, Grant R. Neonatal oncology: diagnostic and therapeutic dilemmas. Semin Perinatol 1997;21:102-11
   PubMedGoogle Scholar
• Brock PR, Yeomans EC, Bellman SC, Pritchard J. Cisplatin therapy in infants: short and long-term morbidity. Br J Cancer 1992;66:S36-40
   Google Scholar
• Ciarimboli G, Ludwig T, Lang D, Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005;167:1477-84
   PubMed Web of Science ®Google Scholar
• Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin Cancer Res 2008;14:3875-80
   PubMed Web of Science ®Google Scholar
• Lee W, Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004;44:137-66
   PubMed Web of Science ®Google Scholar
• Woods WG, O'Leary M, Nesbit ME. Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia. J Pediatr 1981;98:642-5
   PubMed Web of Science ®Google Scholar
• Crom WR, De Graaf SS, Synold T, Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 1994;125:642-9
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Kulle B, Schirmer M, NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754-62
   PubMed Web of Science ®Google Scholar
• Chen HL, Chen HL, Liu YJ, Developmental expression of canalicular transporter genes in human liver. J Hepatol 2005;43:472-7
   PubMed Web of Science ®Google Scholar
• Zhou SF, Chowbay B. Clinical significance of thiopurine S-methyltransferase gene polymorphisms. Curr Pharmacogenomics 2007;5:103-15
   Google Scholar
• Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006;25:1629-38
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Al-Modhwahi I, Andersen MK, Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood 2009;113:6077-84
   PubMed Web of Science ®Google Scholar
• Haga SB, Thummel KE, Burke W. Adding pharmacogenetics information to drug labels: lessons learned. Pharmacogenet Genomics 2006;16:847-54
   PubMed Web of Science ®Google Scholar
• McLeod HL, Coulthard S, Thomas AE, Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999;105:696-700
   PubMed Web of Science ®Google Scholar
• Stanulla M, Schaeffeler E, Flohr T, Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005;293:1485-9
   PubMed Web of Science ®Google Scholar
• Ross CJ, Visscher H, Rassekh SR, Pharmacogenomics of serious adverse drug reactions in pediatric oncology. J Popul Ther Clin Pharmacol 2011;18:e134-51
   PubMedGoogle Scholar
• Gurwitz D, Rodriguez-Antona C, Payne K, Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. Eur J Hum Genet 2009;17:991-8
   PubMed Web of Science ®Google Scholar
• Donnan JR, Ungar WJ, Mathews M, A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;57:231-9
   PubMedGoogle Scholar
• Lamba JK, Crews K, Pounds S, Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther 2007;323:935-45
   PubMed Web of Science ®Google Scholar
• Maring JG, Groen HJM, Wachters FM, Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 2005;5:226-43
   PubMed Web of Science ®Google Scholar
• Peters U, Preisler-Adams S, Hebeisen A, Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 2000;11:639-43
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Kraggerud SM, Cvancarova M, Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007;25:708-14
   PubMed Web of Science ®Google Scholar
• Ross CJ, Katzov-Eckert H, Dube MP, Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009;41:1345-9
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Mori T, Samejima H, Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006;28:64-8
   PubMed Web of Science ®Google Scholar
• Robaey P, Krajinovic M, Marcoux S, Moghrabi A. Pharmacogenetics of the neurodevelopmental impact of anticancer chemotherapy. Dev Disabil Res Rev 2008;14:211-20
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;57:612-19
   PubMed Web of Science ®Google Scholar
• Ongaro A, De Mattei M, Della Porta MG, Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica 2009;94:1391-8
   PubMed Web of Science ®Google Scholar
• Kishi S, Cheng C, French D, Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007;109:4151-7
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Mori T, Torii C, Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2008;30:347-52
   PubMed Web of Science ®Google Scholar
• Huang L, Tissing WJ, de Jonge R, Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 2008;22(9):1798-800
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Ballesteros J, Garcia-Orad A. MTHFR 677TT genotype and toxicity of methotrexate: controversial results. Cancer Chemother Pharmacol 2011;68:1369-70; author reply 1371
   PubMed Web of Science ®Google Scholar
• Kamdar KY, Krull KR, El-Zein RA, Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy. Pediatr Blood Cancer 2011;57:454-60
   PubMed Web of Science ®Google Scholar
• da Silva Silveira V, Canalle R, Scrideli CA, Polymorphisms of xenobiotic metabolizing enzymes and DNA repair genes and outcome in childhood acute lymphoblastic leukemia. Leuk Res 2009;33:898-901
   PubMed Web of Science ®Google Scholar
• Pietrzyk JJ, Bik-Multanowski M, Skoczen S, Polymorphism of the thymidylate synthase gene and risk of relapse in childhood ALL. Leuk Res 2011;35:1464-6
   PubMed Web of Science ®Google Scholar
• Xie H, Griskevicius L, Hle L, Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci 2006;27:54-61
   PubMed Web of Science ®Google Scholar
• Nakajima M, Komagata S, Fujiki Y, Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics 2007;17:431-45
   PubMed Web of Science ®Google Scholar
• van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 2008;11:77-98
   PubMed Web of Science ®Google Scholar
• Dennison JB, Kulanthaivel P, Barbuch RJ, Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 2006;34:1317-27
   PubMed Web of Science ®Google Scholar
• Hempel G, Relling MV, de Rossi G, Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr Blood Cancer 2010;54:355-60
   PubMed Web of Science ®Google Scholar
• Avramis VI, Weinberg KI, Sato JK, Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. Cancer Res 1989;49:241-7
   PubMed Web of Science ®Google Scholar
• Avramis VI, Biener R, Krailo M, Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia. Cancer Res 1987;47:6786-92
   PubMed Web of Science ®Google Scholar
• Avramis VI, Weinberg KI, Siegel SE. Biochemically directed loading bolus (LB) plus continuous infusion (CI) of ara-C regimen in pediatric patients (Pts) with acute leukemia (ALL) or lymphoma. Med Pediatr Oncol 1988;16:418
   Google Scholar
• van den Berg H, van den Anker JN, Beijnen JH. Cytostatic drugs in infants: a review on pharmacokinetic data in infants. Cancer Treat Rev 2012;38:3-26
   PubMed Web of Science ®Google Scholar
• Groninger E, Proost JH, de Graaf SS. Pharmacokinetic studies in children with cancer. Crit Rev Oncol Hematol 2004;52:173-97
   PubMed Web of Science ®Google Scholar
• Trevino LR, Shimasaki N, Yang W, Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009;27:5972-8
   PubMed Web of Science ®Google Scholar
• van de Steeg E, Wagenaar E, van der Kruijssen CM, Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 2010;120:2942-52
   PubMed Web of Science ®Google Scholar
• Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978;41:36-51
   PubMed Web of Science ®Google Scholar
• Thompson PA, Murry DJ, Rosner GL, Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2007;59:847-53
   PubMed Web of Science ®Google Scholar
• Donelli MG, Zucchetti M, Robatto A, Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Med Pediatr Oncol 1995;24:154-9
   PubMedGoogle Scholar
• Lonnerholm G, Valsecchi MG, De Lorenzo P, Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia. Pediatr Blood Cancer 2009;52:596-601
   PubMed Web of Science ®Google Scholar
• Bleyer AW. Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 1977;61:1419-25
   PubMedGoogle Scholar
• Kosaka Y, Koh K, Kinukawa N, Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 2004;104:3527-34
   PubMedGoogle Scholar
• Pascussi JM, Gerbal-Chaloin S, Duret C, The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol 2008;48:1-32
   PubMed Web of Science ®Google Scholar
• Cella M, Knibbe C, de Wildt SN, Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models. Br J Clin Pharmacol 2012; In Press
   Web of Science ®Google Scholar
• Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet 2009;48:71-88
   PubMed Web of Science ®Google Scholar